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aim of the current study is to describe the neuropathologi-
cal features of the anti-IgLON5 syndrome and to provide 
diagnostic levels of certainty based on the presence of asso-
ciated clinical and immunological data. The brains of six 
patients were examined and the features required for the 
neuropathological diagnosis were established by consen-
sus. Additional clinical and immunological criteria were 
used to define “definite”, “probable” and “possible” diag-
nostic categories. The brains of all patients showed remark-
ably similar features consistent with a neurodegenera-
tive disease with neuronal loss and gliosis and absence of 
inflammatory infiltrates. The most relevant finding was the 
neuronal accumulation of hyperphosphorylated tau com-
posed of both three-repeat (3R) and four-repeat (4R) tau 
Abstract We recently reported a novel neurological syn-
drome characterized by a unique NREM and REM paras-
omnia with sleep apnea and stridor, accompanied by bulbar 
dysfunction and specific association with antibodies against 
the neuronal cell-adhesion protein IgLON5. All patients 
had the HLA-DRB1*1001 and HLA-DQB1*0501 alleles. 
Neuropathological findings in two patients revealed a novel 
tauopathy restricted to neurons and predominantly involv-
ing the hypothalamus and tegmentum of the brainstem. The 
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isoforms, preferentially involving the hypothalamus, and 
more severely the tegmental nuclei of the brainstem with 
a cranio-caudal gradient of severity until the upper cervi-
cal cord. A “definite” diagnosis of anti-IgLON5-related 
tauopathy is established when these neuropathological fea-
tures are present along with the detection of serum or CSF 
IgLON5 antibodies. When the antibody status is unknown, 
a “probable” diagnosis requires neuropathological findings 
along with a compatible clinical history or confirmation of 
possession of HLA-DRB1*1001 and HLA-DQB1*0501 
alleles. A “possible” diagnosis should be considered in 
cases with compatible neuropathology but without infor-
mation about a relevant clinical presentation and immuno-
logical status. These criteria should help to identify undi-
agnosed cases among archival tissue, and will assist future 
clinicopathological studies of this novel disorder.
Keywords IgLON5 · Parasomnia · NREM · Tauopathy · 
Brainstem
Introduction
An intriguing progressive neurological disorder at the 
crossroads of autoimmunity and neurodegeneration was 
recently described in eight patients affected by a previ-
ously unknown disorder characterized by non-REM sleep 
(NREM) parasomnias, sleep apnea, and stridor [16]. All 
patients had serum and CSF antibodies, mainly of the 
IgG4 subclass, against IgLON5, a neuronal cell-adhesion 
molecule with unknown function. In addition, all patients 
had the same HLA-DRB1*1001 and HLA-DQB1*0501 
haplotype, which is very rare in the normal population 
[16]. Although these findings suggested an autoimmune 
disease, the symptoms did not respond to immunotherapy. 
Moreover, post-mortem findings in two patients suggested 
a novel tauopathy restricted to neurons and predominantly 
involving the hypothalamus and tegmentum of the brain-
stem without evidence of inflammation [16]. Since then, 
eight additional cases have been identified (four of them 
reported) based on the combined recognition of the charac-
teristic sleep disorder, presence of IgLON5 autoantibodies 
and, when available, demonstration of the same haplotypes 
described above [2, 7, 14, 17].
While these clinical, immunological, and genetic fea-
tures were being established, results of the post-mortem 
neuropathological examination of a third patient became 
available confirming the initial findings of a possible 
novel tauopathy. Therefore, a Task Force was organized 
to describe in detail the neuropathological features of the 
disorder with the aim of developing neuropathological 
diagnostic criteria which should also help to identify this 
disease in retrospective studies of archival tissue from 
patients whose diagnosis was not obtained during life.
Materials and methods
The present study includes the neuropathological study 
of the brain of six patients. It comprises three previously 
reported cases, two of them from the archives of the 
IDIBAPS Neurological Tissue Bank, Barcelona, Spain 
[16] and one who had been identified and followed at the 
Department of Neurology, Medical University of Inns-
bruck, and underwent post-mortem examination at the 
Institute of Neurology, University of Vienna, Austria [7]. 
These three initial cases were comprehensively reviewed 
and a consensus regarding a preliminary set of neuropatho-
logical criteria was established. Based on these criteria two 
additional patients from Queen Square Brain Bank and the 
Division of Neuropathology, UCL Institute of Neurology, 
University College London, UK and a third one from the 
Institute of Pathology of the University of Ljubljana, Slo-
venia, were identified. Clinicopathological data of two of 
these patients who had died several years before the discov-
ery of the anti-IgLON5 syndrome, were described as single 
case reports [13, 15].
In order to establish the neuropathological diagnostic 
criteria a meeting was held by four neuropathologists (EG, 
RH, GGK, TR), who were familiar with all of the six cases. 
Using a multi-header microscope the cases were re-evaluated 
and the histological features required for the neuropathologi-
cal diagnosis of this novel tauopathy were agreed on by con-
sensus. Subsequently, these neuropathological criteria along 
with clinical, immunological, and HLA haplotype findings 
were used by all the investigators [neuropathologists and cli-
nicians (JD, FG, JS, BH)] to define three diagnostic levels of 
disease: “possible”, “probable”, and “definite”.
All six brains were processed according to standard 
neuropathological procedures. Formalin-fixed and paraf-
fin-embedded tissue blocks representing frontal, temporal, 
parietal and occipital cortices, caudate, lenticular nucleus, 
hypothalamus, thalamus, hippocampus, parahippocampal 
gyrus, amygdala, midbrain, pons, medulla oblongata, spi-
nal cord, and cerebellum were retrieved from the archives 
of the four centers and were cut as 5 μm thick sections. 
Sections were stained with haematoxylin and eosin method 
and in selected cases and areas tissue sections were also 
stained with Bielschowsky’s or Gallyas silver impregnation 
and Luxol-fast-blue/cresyl violet method. For immunohis-
tochemistry a panel of primary antibodies was used in each 
laboratory (Table 1). Cases 1 and 2 were processed in Bar-
celona, case 3 in Vienna, case 4 originally in Ljubljana and 
later in Vienna, and cases 5 and 6 in Preston and London.
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Results
The main clinical and immunological characteristics of the 
six patients are summarized in Table 2. Three patients were 
male and the median age at the onset of symptoms was 
53 years (range 48–77 years). The three patients diagnosed 
in life with positive IgLON5 antibodies were studied with 
video-polysomnography and presented a unique temporal 
sequence of sleep stages and behaviors, from very abnor-
mal at the beginning of the night to close to normal by the 
end. The initiation and re-entering of sleep after awaken-
ing were characterized by undifferentiated non-rapid eye 
movement (NREM) sleep with frequent vocalizations, 
stereotyped movements, and finalistic behaviors (parasom-
nias). The REM sleep was present but only in the form of 
REM sleep behavior disorder. In addition, most patients 
had a sleep breathing disorder characterized by stridor and 
obstructive sleep apnea.
The clinical history of the three patients in whom 
IgLON5 antibodies were not tested was dominated by bul-
bar dysfunction and repetitive episodes of respiratory insuf-
ficiency that required tracheostomy or multiple admissions 
to ICU. Other symptoms included gait instability, frequent 
falls, dysphagia, gaze palsies, central hypoventilation, 
dysautonomia, and chorea. These symptoms can suggest 
other diagnoses such as progressive supranuclear palsy or 
multiple system atrophy, although no parkinsonian signs 
were present. In none of these patients was the sleep for-
mally studied, but in two of the cases symptoms of exces-
sive daytime sleepiness, stridor, sleep apnea or parasomnia 
were documented (Table 2).
Table 3 summarizes the neuropathological features of 
the six cases. The detailed neuropathological reports of 
the two cases not previously reported and the re-evaluation 
of the previously published UK case [13] are presented 
below.
Case 3 (Vienna–Innsbruck, Austria)
Detailed clinical information of the disease course has been 
previously reported [7] and is summarized in Table 2. Post-
mortem examination of the cerebrum was performed after 
obtaining informed consent from the next of kin. Gross 
examination showed mild atrophy of superior cerebellar 
peduncles and brainstem tegmentum. Histology revealed a 
prominent tauopathy, characterized by numerous Gallyas-
positive neurofibrillary tangles (NFT), diffuse granular 
cytoplasmic phospho-tau (pTau) immunoreacitivity (pre-
tangles), and neuropil threads involving predominantly the 
hypothalamus, zona incerta, hippocampus, tegmentum of 
brainstem (mesencephalon, pons and medulla), and cervi-
cal spinal cord (Table 3; Fig. 1) in a symmetrical fashion. 
The hippocampus showed a high density of NFT and pre-
tangles in the pyramidal cell layer (Fig. 2a), accentuated in 
the CA2 and CA4 sectors, and moderate amounts of pre-
tangles in the dentate gyrus. Only occasional ghost tangles 
were detected. The pathology in the midbrain, pons, and 
medulla oblongata was mainly restricted to the tegmentum 
including periaqueductal gray matter, laterodorsal tegmen-
tal nucleus, pedunculopontine nuclei, median raphe nuclei, 
dorsal motor nucleus of the vagus nerve, nucleus ambiguus 
and neurons of the magnocellular nucleus (Fig. 2c). Sub-
stantia nigra was only mildly affected, and the subthalamic 
nucleus and basis pontis showed isolated threads and pre-
tangles (Fig. 2d). The inferior olivary nucleus was well 
preserved but had frequent clusters of fine threads sur-
rounding individual neurons (Fig. 2e). The cerebellar cor-
tex was globally well preserved, but showed a fine granular 
synaptic-like pTau immunoreactivity pattern involving the 
glomerula of the granular cell layer of the vermis (Fig. 2f). 
In addition, a few Purkinje cells showed diffuse cytoplas-
mic pTau positivity. There was a prominent involvement of 
the cervical spinal cord with marked pTau pathology in the 
Table 1  Antibodies used for neuropathological characterization
mc monoclonal, pc polyclonal
Name Clonality/clone Company Dilution
Anti-βA4-amyloid mc, clone 6F/3D DAKO, Glostrup, Denmark 1:400
Anti-phosphorylated tau mc, clone AT8, pS202/pT205 Thermo Scientific, Rockford, IL, USA 1:200
Anti-ubiquitin pc DAKO, Glostrup, Denmark 1:400
Anti-alpha-synuclein mc, clone KM51 Novocastra, Newcastle, UK 1:500
Anti-TDP-43 mc, clone 2E2-D3 Abnova, Taipei, Taiwan 1:500
Anti-RD3 tau mc, clone 8E6/C11 Millipore, Temecula, CA, USA 1:1000
Anti-RD4 tau mc, clone 1E1/A6 Millipore, Temecula, CA, USA 1:50
Anti-alpha-internexin mc, clone 2E3 Invitrogen, CA, USA 1:800
Anti-p62 mc, clone 3/p62 lck ligand BD Transduction Laboratories TM, NJ, USA 1:500
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dorsal horns and lesser involvement of the anterior horns 
(Fig. 1j), with decreasing intensity further caudally in the 
lumbar spinal cord, where pathology became less evident 
but was still visible in the dorsal horn. pTau immunoreac-
tivity was almost entirely confined to neurons and the tau-
positive structures were also labeled with both, the 3R-tau 
(Fig. 2h) and 4R-tau (Fig. 2i) antibodies. All these areas 
showed moderate microglial activation. Neuronal loss cor-
related with the presence of NFT. The cranial nerves were 
not affected. Only very occasional coiled bodies and tau-
positive granular fuzzy astrocytes were visible in the hypo-
thalamus, substantia nigra, and anterior horn of the spinal 
cord. Other morphological alterations included a few bal-
looned neurons in the amygdala. Anti-LCA revealed only 
a few meningeal and perivascular leukocytes mainly com-
posed of CD3 and CD8 positive T cells and a few CD20 
and CD79A B cells in the hypothalamus, brainstem, and 
cerebellum without any parenchymal involvement that 
could suggest an inflammatory process. No obvious IgG4 
deposits were detected, except for a faint staining of the 
cerebellar glomerula of the vermis (data not shown). Com-
plement deposits were not visible. 
Case 5 (London, UK)
A 48-year-old man developed recurrent vertigo and marked 
involuntary fidgety movements. At the age of 53 he devel-
oped breathing and swallowing difficulties. Multiple 
Table 2  Clinical features of the six patients
V-PSG video-polysomnography
a See Table 4
Patient # 1 (case 216) 2 (case 716) 37 415 5 613
Gender Male Female Female Female Male Male
Age (years) at 
onset
53 76 54 77 48 49
Presenting symp-
toms
Sleep disorder Sleep disorder Sleep disorder Dysphagia,  
dyspnea,
Vertigo, abnormal 
movements
Dysphagia, dyspnea
Disease duration 6 years 6 months 13 years 10 years 12 years 10 years
Excessive day 
sleepiness
Mild No Yes No Yes Yes
Parasomnia Yes (V-PSG) Yes (V-PSG) Yes (V-PSG) Unknown Yes (clinical 
report)
Unknown
Sleep apnea Yes (V-PSG) Yes (V-PSG) Yes (V-PSG) Unknown Unknown Yes
Stridor Yes Yes Yes (endoscopy) Yes (endoscopy) Unknown Unknown
Respiratory insuf-
ficiency
Yes Yes (needed tra-
cheostomy)
Yes (needed tra-
cheostomy) 
 Yes (needed 
tracheostomy) 
Yes (multiple ICU 
admissions)
Yes
Cognitive deterio-
ration
No No No No No No
Gait instability Yes Yes Yes No Yes No
Chorea No No No No Yes No
Parkinsonism No No No No No No
Limb ataxia No No No No Yes No
Ocular movements Normal Saccadic intru-
sions on pursuit
Normal (bilateral 
ptosis)
Horizontal nystag-
mus
Horizontal nystag-
mus, restricted 
up and lateral 
gaze
Normal (bilateral 
ptosis and hori-
zontal nystagmus)
Bulbar symptoms Dysphagia Dysphagia, dys-
arthria
Dysphagia, dys-
arthria
Dysphagia Dysphagia (gas-
trostomy feed-
ing), dysarthria
Dysphagia (gastros-
tomy feeding)
Dysautonomia Enuresis No No No Hypersalivation No
Outcome Sudden death  
during sleep
Sudden death  
during sleep
Death of respira-
tory failure
Sudden death  
during sleep
Died of respira-
tory arrest during 
hospital admis-
sion
Death of respiratory 
failure at home
IgLON5 antibod-
ies
Positive Positive Positive Not done Not done Not done
Diagnostic levela Definite Definite Definite Probable Probable Probable
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Table 3  Neuropathological characteristics including topographical distribution of hyperphosphorylated tau pathology
a Cases 1 and 2 unfixed; 3–6 fixed; b pretangles
Case 1 (case 216) Case 2 (case 716) Case 3 Case 415 Case 5 Case 613
Brain weight (in g)a 1410 1180 1290 1220 1422 1415
Macroscopic findings Diffuse oedema Mild prefrontal atrophy Mild brainstem atrophy Unremarkable Unremarkable Unremarkable
Brain region pTau (AT8) pathology (RD3/RD4 isoforms in all cases)
 Frontal cortex 0 0 Isolated Isolated Isolated Isolated
 Temporal cortex 0 0 Isolated Isolated Isolated Isolated
 Parietal cortex 0 0 Isolated N/A N/A 0
 Occipital cortex 0 0 Isolated N/A N/A 0
 Ant cingulate cortex Isolated Isolated Isolated Isolated Isolated Isolated
 Hippocampus CA4 ++ + ++ + ++ ++
 Hippocampus CA2 +++ Isolated +++ +++ +++ +++
 Hippocampus CA1 ++ + ++ ++ ++ ++
 Dentate gyrus ++ Isolated ++ + +++ +++
 Entorhinal cortex ++ + ++ + ++ ++
 Transentorhinal Isolated Isolated ++ Isolated Isolated Isolated
 Amygdala Isolated + + ++ + Isol
 n. basalis Meynert ++ + ++ + N/A +
 Substantia innominata ++ ++ +++ +++ N/A N/A
 Septal nuclei ++ Isolated ++ ++ N/A N/A
 Striatum 0 Isolated Isolated Isolated + 0
 Pallidum, external Isolated Isolated Isolated Isolated + Isolated
 Pallidum, internal + + + + ++ Isolated
 Thalamus Isolated Isolated Isolated Isolated + Isolated
 Zona incerta Isolated ++ +++ +++ ++ +
 Subthalamic nucleus Isolated + + Isolated + +
 Hypothalamus ++ ++ +++ +++ +++ N/A
  n. paraventricularis + + + + N/A N/A
  n. supraopticus + + + + N/A N/A
  n. dorsomedialis +++ + +++ +++ N/A N/A
  n. ventromedialis +++ ++ +++ +++ N/A N/A
  n. tuberales ++ ++ ++ ++ N/A N/A
  n. posterior + ++ +++ +++ N/A N/A
 Corpus mamillare 0 Isolated Isolated Isolated N/A N/A
 Brainstem
  Laterodorsal  
tegmental n.
++ +++ +++ +++ +++ ++
  Pedunculopontine n. ++ +++ +++ +++ +++ +++
  Periaqueductal gray + ++ +++ +++ +++ +++
  Substantia nigra Isolated Isolated + + ++ +
  Locus coeruleus + + ++ ++ ++ +
  Central raphe (pons) ++ + +++ + ++ ++
  n. propii basis pontis +++b 0 Isolated 0 +++ b Isolated
  Dorsal n. vagal nerve + + +++ +++ ++ ++
  n. ambiguus ++ +++ +++ +++ +++ ++
  Gigantocellular nuclei +++ +++ +++ +++ +++ +++
  Inferior olives Isolated Isolated Isolated Isolated + Isolated
 Cerebellum—cortex ++ 0 + Isolated + Isolated
  Dentate nucleus Isolated Isolated Isolated Isolated + Isolated
 Cervical spinal cord + +++ +++ +++ N/A ++
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episodes of aspiration pneumonia and respiratory arrests 
warranted four admissions to the intensive care unit and, 
on two occasions, intubation for ventilator support was 
required. Due to recurrent aspiration, a gastrostomy tube 
was inserted for feeding. One year later, he developed 
progressive difficulties with his balance and intermittent 
diplopia. He had lateral and upgaze nystagmus with limi-
tation of vertical and abduction eye movements. There 
was cerebellar dysarthria, finger-nose dysmetria, and 
he was unable to tandem walk. Choreiform movements 
Fig. 1  Distribution of tau related pathology in case 3. Coronal sec-
tions through the substantia innominata and hypothalamus (a), 
thalamus with nucleus ruber and substantia nigra (b), cerebellum 
with pons (c), higher magnification of hippocampus (d, e), pons (f), 
medulla oblongata at the level of olivary nucleus (g, h), cerebel-
lar cortex (i), and cervical spinal cord (j, k). The tau pathology pre-
dominantly affects the hypothalamus, substantia innominata (a), zona 
incerta, hippocampus (b), and the tegmentum of the brain stem (c); 
Tangles and threads are abundantly present in the pyramidal layer 
with the highest density in the CA2 sector (d). Pretangles are also 
present in the dentate gyrus (rectangle in d enlarged in e). High den-
sities of tangles and threads are present in the tegmentum of pons (f) 
and medulla oblongata (g). Bush-like delicate processes accumulat-
ing around neurons are visible in the olivary nucleus (rectangle in g 
enlarged in h). Grain-like processes are mainly found in the vermis of 
the cerebellar cortex, occasionally, a few Purkinje cells show a cyto-
plasmic tau immunoreactivity (rectangle in c enlarged in i). Moderate 
tau pathology is apparent mainly in the dorsal horn of the spinal cord 
(j, enlarged in k)
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were present in all limbs. Deterioration in excessive day-
time somnolence caused him to fall asleep even when he 
was standing. His wife reported that his breathing pattern 
changed as soon as he was asleep but no abnormal move-
ments were noted. During a hospital admission to investi-
gate his sleep attacks, he had a respiratory arrest and died 
at the age of 60.
Neuropathological examination was performed after 
appropriate written informed consent from the next of kin 
had been obtained. Consent for the use of this case for 
research purposes was also given. The brain was macro-
scopically unremarkable. Microscopic studies showed an 
increase in number of reactive astrocytes in the striatum 
and globus pallidus. There was some loss of neurons with 
accompanying astrogliosis in the dorsolateral aspect of the 
subthalamic nucleus while the substantia nigra was well 
populated with pigmented and non-pigmented neurons. 
There was some reduction of the height of the pontine teg-
mentum, which was marked in the medulla oblongata. Tau 
immunohistochemistry using the AT8 antibody demon-
strated only occasional NFT and pretangles in neocortical 
areas. All hippocampal subregions were affected by neu-
ronal tau pathology; there were moderate numbers of pre-
tangles and NFT in the CA1 hippocampal subregion, which 
were sparse in the CA3 and CA4 subregions. There were 
frequent pretangles in CA2 and also in the granule cells of 
the dentate gyrus, which were ubiquitin and p62-negative. 
Fine neuropil threads were present in all hippocampal sub-
regions. The tau pathology was similar, but mild in the 
subiculum while moderate numbers of Gallyas-positive 
NFT and neuropil threads were seen in the entorhinal cor-
tex. There were scattered tau-positive neuropil threads, 
Fig. 2  Morphology of tau related pathology in case 3. pTau related 
pathologies include NFT and pretangles (a CA2 sector of the hip-
pocampus; b substantia innominata), diffuse fine granular cytoplas-
mic immunoreactivity (c gigantocellular nucleus of reticular forma-
tion), and numerous somato-synaptic immunoreactivity in the brain 
stem nuclei (d hypoglossal nucleus), bush-like delicate processes 
accumulating around neurons (e olivary nucleus), fine granular 
synaptic-like-deposits (f cerebellar cortex) and long coarse and fine 
threads (g substantia innominata). These immunomorphologies stain 
positive for three-repeat- (h) and four-repeat (i) tau isoforms. a–g: 
AT8 ×400; h: 3RT ×400; i: 4RT ×400
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pretangles and occasional NFT in the striatum. Similar, 
but slightly more severe pTau pathology was seen in the 
globus pallidus. The subthalamic nucleus contained mod-
erate numbers of pretangles, NFT and neuropil threads. 
A conspicuous feature was the severe tau deposition in 
the posterior hypothalamus and brainstem structures. In 
the midbrain a significant proportion of the substantia 
nigra pars compacta neurons showed granular or dot-like 
tau positivity, which was also seen in neuronal processes. 
Similar tau pathology was seen in the midbrain tegmentum, 
periaqueductal gray matter and tectum. The majority of the 
neurons of the otherwise well-populated locus coeruleus 
contained similar neuronal tau-positive inclusions and the 
pontine tegmentum and base were also extensively affected 
by similar tau pathology. The tau deposition was particu-
larly severe in the tegmentum of the medulla including the 
dorsal motor nucleus of the vagus nerve, nucleus tractus 
solitarius, nucleus ambiguus and neurons of the magnocel-
lular nucleus were severely affected. In the inferior olive 
neurons were often surrounded by a meshwork of fine tau-
positive processes and dot-like tau positivity. There were 
scattered pretangles and NFT, neuropil threads and clusters 
of fine tau-positive dots in the cerebellar dentate nucleus. 
There was rather widespread granular tau positivity in the 
cerebellar cortex and an occasional Purkinje cell showed 
fine, dot-like tau positivity. Differential tau immunohisto-
chemistry confirmed that the pTau deposits were composed 
of both 3R-tau and 4R-tau isoforms.
Case 6 (London, UK)
For clinical history and the distribution of the NFT pathol-
ogy see Lidov et al. [13]. Tau immunohistochemistry with 
the AT8 antibody was carried out using tissue sections of 
paraffin blocks available in the archives of the Division of 
Neuropathology, UCL Institute of Neurology. The distribu-
tion of the pTau pathology, including involvement of the 
hippocampus was rather similar to that described in case 5. 
However, there were some differences, which included that 
in this case the striatum was virtually devoid of tau pathol-
ogy and the involvement of the globus pallidus and subtha-
lamic nucleus was considerably milder than that observed 
in case 5. The brainstem tegmentum showed severe deposi-
tion of disease-associated tau in a distribution as described 
above, but the substantia nigra and pontine base showed 
only sparse tau-positive pretangles, NFT and neuropil 
threads. There was tau pathology of moderate degree in 
the posterior horns of the cervical and thoracic cord (these 
were the levels that were available for review) and sparse 
neuropil threads and occasional NFT were also seen in the 
anterior horns. Occasional tau-positive granular depos-
its were found in the cerebellar cortex. The tau inclusions 
were both 3R-tau and 4R-tau immunoreactive.
Summary of neuropathological features and suggested 
neuropathological criteria
The neuropathological findings in the six patients showed 
remarkable similarity consistent with a neurodegenerative 
disease with neuronal loss and gliosis, without the presence 
of inflammatory infiltrates. The most relevant finding was a 
prominent neuronal accumulation of pTau, comprising both 
3R-tau and 4R-tau isoforms, involving the hypothalamus 
and more severely the tegmental brainstem nuclei, with a 
cranio-caudal gradient of severity, reaching the upper cer-
vical cord. The cerebral cortex, basal ganglia, thalamus 
and subthalamic nucleus were mostly unaffected or mildly 
affected. In five cases the entorhinal cortex and hippocam-
pus were also affected including dentate gyrus and CA4 to 
CA1 sectors, with variable involvement of transentorhinal 
region. Interestingly, CA2 sector was consistently involved. 
There was a lack of glial tau pathology except for the pres-
ence of isolated coiled bodies and granular fuzzy astrocytes 
in the hypothalamus and amygdala in cases 3 and 4. A 
detailed semiquantitative assessment of pTau pathology in 
different brain areas of all cases is represented in Table 3 
and Fig. 3 shows a schematic heat-map representation of 
the distribution and severity of pTau pathology throughout 
the brain for all cases.
There were no other abnormal deposits of proteins, or if 
present these were mild and localized in a few areas sug-
gesting the co-existence of other neurodegenerative or age-
related pathologies. Case 2 showed isolated Bunina bodies 
and TDP43 protein aggregates in few brainstem and motor 
neurons in the spinal cord. A few neuritic plaques were 
observed in cases 2, 4, and 6, along with cerebral amyloid 
angiopathy in cases 2 and 4. Case 4 additionally showed 
scattered alpha-synuclein positive Lewy bodies and Lewy 
neurites in the substantia nigra and dorsal nucleus of the 
vagus nerve and argyrophilic grain pathology, and case 5 
showed sparse neuronal cytoplasmic TDP43 protein inclu-
sions in the granule cells of the dentate gyrus.
Based on the similarities of these cases we propose 
research criteria for the neuropathological diagnosis of 
the tauopathy underlying the anti-IgLON5 syndrome 
(Table 4) and recommend a protocol of tissue sampling 
(Table 5). When a neuropathologist is confronted with a 
case with such a neuropathological phenotype in conjunc-
tion with positive IgLON5 antibodies in CSF or serum, 
the diagnosis of “definite anti-IgLON5-related tauopa-
thy” should be considered. In contrast, when the informa-
tion of the anti-IgLON5 antibodies status is missing but 
the clinical history is compatible or the patient harbored 
the HLA-DRB1*1001 and HLA-DQB1*0501 alleles, then 
the diagnostic category of “probable anti-IgLON5-related 
tauopathy” should be applied. The category of “possible 
anti-IgLON5-related tauopathy” should be reserved for 
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those cases where clinical data are not available (e.g. due 
to the retrospective identification of archival cases or other 
reasons) and ancillary tests (anti-IgLON5 antibodies and/
or HLA-DRB1*1001 and HLA-DQB1*0501 alleles) could 
not be performed. Note that both the HLA genotyping 
and the anti-IgLON5 antibody assay could be done post-
mortem from DNA samples and serum or ventricular CSF, 
respectively. No exclusion criteria have been proposed as 
the whole spectrum of pathological changes and possible 
concomitant pathologies are yet unknown.
Discussion
We report here the main neuropathological features under-
lying the anti-IgLON5 syndrome that are different from 
those of other tauopathies [4, 11]. The three main findings 
are (1) the subcortical topographical distribution of the tau 
pathology with predominant involvement of the hypothala-
mus and brainstem tegmentum, with a rostro-caudal gradi-
ent of severity to include the upper cervical cord, (2) the 
nearly exclusive neuronal tau pathology with little or no 
Fig. 3  Schematic distribution of tau pathology in anti-IgLON5 
related tauopathy. Coronal sections through the amygdala and the 
lateral geniculate body (a), midbrain (b), pons (c), medulla oblon-
gata [level of olivary nucleus (d) and decussation of pyramids (e)], 
and cervical spinal cord (f). Scoring of the frequency of tau pathol-
ogy in sections stained with tau AT8 is based on the number of tan-
gles and threads: red many; orange moderate; orange dots moderate/
few; green dots few; and blue dots isolated. A nucleus ambiguus, AC 
anterior commissure, Amy amygdala, CA anterior horn, CC crus cer-
ebri, CI inferior colliculus, CN cuneate nucleus, CP posterior horn, 
ER entorhinal cortex, F fornix, GP pallidum, GN gracile nucleus, HC 
hippocampus, Hyp hypothalamus, LC locus coeruleus, LTN laterodor-
sal tegmental nucleus, NPB parabrachial nuclei, NS solitary nucleus, 
ON olivary nucleus, P putamen, PAG periaquaeductal gray, PI pars 
intermedia, PPN pedunculopontine nucleus, RU nucleus ruber, R 
raphe nucleus, RF reticular formation, RF(Gi) gigantocellular reticu-
lar nucleus, SG substantia gelatinosa, SI substantia innominata, SN 
substantia nigra, SNT nucleus of spinal tract of trigeminal nerve, STN 
subthalamic nucleus, TS solitary tract, V trigeminal nucleus, VIII inf 
inferior vestibularis nucleus, VIII med medial vestibularis nucleus, X 
dorsal nucleus vagal nerve, XI spinalis spinal accessory nucleus, XII 
hypoglossal nucleus, ZI zona incerta
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involvement of glia and the white matter, and (3) compo-
sition of disease-associated tau of both 3R-tau and 4R-tau 
isoforms.
We propose that the tauopathy underlying the anti-
IgLON5 syndrome can be diagnosed with three levels of 
probability: definite, probable, and possible. Accordingly, 
for example the previously reported case by Kaphan et al. 
[10] would fulfill criteria of “probable” anti-IgLON5-
related tauopathy as the neuropathological findings and 
clinical features are supportive of the diagnosis. We believe 
that these neuropathological features present in our six 
cases make this entity unique and the tau pathology seen 
did not meet the diagnostic criteria of any of the known 
primary tauopathies. In our cases the neuronal tau pathol-
ogy showed a characteristic distribution with preferential 
involvement of the hypothalamus, tegmentum of the mid-
brain, pons, and medulla oblongata, which affected the 
periaqueductal gray matter, laterodorsal tegmental nucleus, 
pedunculopontine nucleus, median raphe nucleus, dorsal 
motor nucleus of the vagus, nucleus ambiguus, and the 
magnocellular nuclei of reticular formation with only mild 
or no involvement of substantia nigra and inferior olivary 
Table 4  Proposed neuropathological criteria to define the tauopathy underlying the anti-IgLON5 syndrome
a Hippocampus generally involved, except for one patient
b Includes dysarthria, dysphagia, central hypoventilation, stridor
c IgLON5 positivity is detected by cell-based assay in serum at 1/40 and in CSF at 1/2
Possible
 All of the following requirements
  Neurodegenerative features with neuronal loss and gliosis in brain areas showing hyperphosphorylated (p)Tau pathology without the presence 
of inflammatory infiltrates
  Selective neuronal involvement by deposition of pTau in the form NFT, pretangles and neuropil threads with both 3R-tau and 4R-tau iso-
forms contributing to the inclusions
  The pTau pathology predominantly affects subcortical structuresa, including the hypothalamus, brainstem tegmentum and upper spinal cord
Probable
 Criteria of “possible” AND at least one of the following
  Clinical history suggestive of a sleep disorder (NREM and REM parasomnia with sleep apnea), or brainstem, mainly bulbar dysfunctionb
  Presence of HLA-DRB1*1001 and HLA-DQB1*0501 alleles
Definite
 Criteria for “possible” AND presence of IgLON5 antibodies in CSF or serumc
Table 5  Recommended minimal sampling protocol for the diagnosis of anti-IgLON5 related tauopathy
1 Frontal cortex (e.g., middle frontal gyrus)
2 Temporal cortex (e.g., middle temporal gyrus)
3 Pre/postcentral gyri
4 Parietal cortex (e.g., inferior parietal gyrus)
5 Occipital cortex including striate and parastriate cortex
6 Posterior hippocampus at the level of the lateral geniculate body
7 Amygdala
8 Striatum at the level of the nucleus accumbens
9 Basal ganglia at the level of the anterior commissure to include the nucleus basalis and diagonal band
10 Anterior and posterior hypothalamus
11 Anterior, dorsomedial, ventrolateral and posterior thalamus
12 Subthalamus
13 Midbrain at the level of the emergence of the 3rd cranial nerve
14 Pons at the level of the locus coeruleus
15 Medulla at the level of the caudal end of the 4th ventricle to include the 12th nerve nucleus and inferior olive
16 Cerebellar cortex, white matter and dentate nucleus
17 Spinal cord (at least cervical level)
18 Blood and CSF for antibody and HLA testing
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nucleus. These areas have been implicated in sleep regu-
lation and correlate well with clinical symptoms of the 
patients [5]. There is additional involvement of the spi-
nal cord with neuronal accumulation of pTau in the dor-
sal horns, and to a lesser extent, in the anterior horns. The 
tau pathology also shows a cranio-caudal gradient in that 
the cervical spinal cord is more severely affected than the 
lumbar cord. Discrete fine granular tau immunoreactivity is 
also observed in glomerula of the granular cell layer of the 
cerebellar cortex in the vermis. In addition, a few Purkinje 
cells may show diffuse cytoplasmic pTau positivity.
This condition has distinct microscopic appearances 
allowing its differentiation from other ‘primary’ tauopa-
thies, although the topographical distribution of the tau 
pathology is, to some extent, reminiscent of that seen in 
progressive supranuclear palsy (PSP). Indeed, one post-
mortem case has been previously reported as “early” 
PSP [10] and another case clinically mimicking PSP and 
with serum—but not CSF—IgLON5 antibodies has been 
described [2]. However, the anti-IgLON5-related tauopathy 
can clearly be differentiated from PSP, even from its vari-
ants with more restricted tau pathology [4, 18] or other 4R 
tauopathies such as corticobasal degeneration (CBD) [4], 
globular glial tauopathies (GGT) or argyrophilic grain dis-
ease (AgD) by the morphological patterns of the tau pathol-
ogy, including the absence of glial pathology (tufted astro-
cytes or coiled bodies), and sparse supratentorial and basal 
ganglia involvement [11]. A severe brainstem involvement 
clinically causing REM sleep behavior disorder, stridor, 
respiratory insufficiency and death during sleep, cerebel-
lar dysfunction including nystagmus and limb/gait ataxia, 
and autonomic dysfunction is also seen in multiple system 
atrophy, which is associated with alpha-synuclein accumu-
lation in glial cytoplasmic inclusions and less frequently 
neuronal cytoplasmic and nuclear inclusions [8].
As in Alzheimer’s disease, the tau filaments seen in the 
anti-IgLON5 syndrome ultrastructurally appear as paired 
helical filaments [13] and the differential tau immunohisto-
chemistry confirms that they are composed of both 3R-tau 
and 4R-tau isoforms. In addition to Alzheimer’s disease, 
tau inclusions composed of both 3R-tau and 4R-tau iso-
forms occur also in several other disorders such as posten-
cephalitic parkinsonism, chronic traumatic encephalopathy, 
Parkinson-dementia complex of Guam, and FTDP-17 due 
to MAPT mutations. However, these disorders frequently 
have glial involvement, show different topographical distri-
bution of abnormalities, and present with different clinical 
syndromes [11].
In addition to the prominent brainstem involvement, five 
of the six patients had neuronal tau pathology in the hip-
pocampus with frequent pretangles in CA4 and CA2 sector, 
and NFT in CA1 sector and entorhinal cortex, with vari-
able involvement of transentorhinal region, and ring-shaped 
pretangles in the granule cells of the dentate gyrus. Selec-
tive involvement of CA2 sector has been reported to occur 
more frequently in 4R-tauopathies [9]. The tau distribution 
was however more similar to that described in primary 
age-related tauopathy (PART) [3] which is considered a 
common pathology associated with human aging. More 
neuropathological studies are needed to clarify whether 
the hippocampal involvement in our patients indicates the 
presence of an associated PART as an accelerated aging or 
is part of the neuropathological signature of anti-IgLON5-
related tauopathy. The prominence of hippocampal pTau 
pathology and its extension beyond the boundaries of the 
medial temporal lobe in relatively young patients (mean 
age 68.2) argues for the latter possibility. The mild to mod-
erate involvement of the locus coeruleus might also reflect 
an age-related process, since this has been reported as 
another site of early tau hyperphosphorylation and accu-
mulation (pretangle stage) even before puberty or in early 
young adulthood [1]. Similarly, occasional coiled bodies 
and tau-positive fuzzy astrocytes observed in one case sug-
gest the presence of a mild aging-related tau astrogliopathy 
(ARTAG) [12].
The most intriguing aspect of the disease is the asso-
ciation of neuropathological findings suggesting a non-
inflammatory degenerative process with the presence of 
highly specific antibodies against IgLON5 (a neuronal 
cell-adhesion molecule) and a strong association with the 
HLA system. A possible mechanism that could explain tau 
hyperphosphorylation and accumulation in neurons might 
relate to one of the functions of IgLON family as gluco-
syl-phosphatidyl-inositol anchored proteins and its role in 
membrane stabilization [6]. An antibody-induced dysfunc-
tion of IgLON5 may disrupt the interaction of this protein 
with the internal cytoskeletal network, de-stabilize the 
neuronal microtubular system and induce hyperphospho-
rylation and accumulation of the microtubule-associated 
protein tau, leading to neuronal dysfunction and ultimately 
to neurodegeneration. The distribution of pTau pathology 
could raise the possibility of a trans-synaptic spread of tau 
from selectively vulnerable neuronal populations by neu-
ronal connectivity, i.e. from several brainstem nuclei (e.g. 
dorsal raphe, reticular formation, locus coeruleus), caudally 
to posterior and intermediate spinal cord gray matter and 
rostrally to hypothalamic nuclei, although no overt involve-
ment of other interconnected areas has been observed (e.g. 
amygdala, striatum, thalamus, neocortex) (supplementary 
Fig. 1).
However, the intriguing coexistence of neuropathologi-
cal and immunological findings and the precise mechanism 
of the cross-talk between these two potential pathogenic 
mechanisms need to be elucidated.
In summary, since the publication of two cases of 
a novel, brainstem accentuated neuronal 3R and 4R 
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tauopathy associated with IgLON5 autoantibodies in 
patients with apnea and NREM parasomnia, a new case 
has been confirmed in Austria and three additional cases, 
one from Slovenia and two from the UK have been retro-
spectively identified on the basis of their nearly identical 
neuropathological phenotype. We suggest including these 
cases under the umbrella term of a single clinicopatho-
logical entity termed “anti-IgLON5-related tauopathy”. To 
facilitate communication with clinicians and researchers 
and to provide a framework for future clinicopathologi-
cal and research studies we propose here research criteria 
for the neuropathological diagnosis of this unique tauopa-
thy and recommend a protocol for tissue sampling. This 
information could also be of value in the re-evaluation of 
archival cases. Clearly, the recognition of more cases will 
be of utmost importance to identify the entire spectrum of 
the clinicopathological presentation and to elucidate the 
role of IgLON5 antibodies in initiating a cellular cascade 
finally resulting in abnormal hyperphosphorylation, aggre-
gation and accumulation of tau. Only a better understand-
ing of this interplay can result in the design of appropriate 
treatment strategies that can modify disease progression 
and consequently mitigate the risk of sudden death during 
sleep.
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